European and South Korean authorities are vying for Gilead Sciences’ potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is still ramping up production of the anti-viral drug.
European, South Korean authorities vie for COVID-19 antiviral remdesivir